The Society of Gynecologic Oncology of Canada

https://www.gyneoncology.ca

Contact us

This is a past event. Registration is closed. View other The Society of Gynecologic Oncology of Canada events.

Event Details

Registration for the 22nd Continuing Professional Development Meeting is now closed!


Are you registered for the meeting? Go to the email from SpotMe (noreply@spotme.com) that was previously sent to you to give you access to the event. Please access the event platform to get the zoom link and to see the agenda in your own time zone. Once on the platform, click on today's date and on the first session to get the zoom link which is at the bottom of the page. Note that your web access link is unique and cannot be shared.

Questions? Send us an email at enquiry@gyneoncology.ca.



It is with great pleasure that we invite you on behalf of the Executive of The Society of Gynecologic Oncology of Canada and the CPD Program Planning Committee to attend the 22nd Annual Continuing Professional Development meeting. We have an outstanding array of local, national, and international speakers who will be presenting a variety of exciting topics with this year's theme as: Expanding Treatment Paradigms in Gynecologic Oncology.


At the end of this program, participants will be able to:

  • Discuss the management of obese patients.
  • Identify sarcopenic obesity as a precursor to gynecologic cancer and review the role of nutrition in mitigating it.
  • Integrate frailty into the treatment plan of patients.
  • Review the latest findings on PARP Inhibitors in ovarian cancer.
  • Examine the role of immune therapy in the management of endometrial cancer.
  • Analyze the management of immune-related toxicities.


This is a virtual meeting. Please note that all times in the agenda below are in PST. You can download the agenda in various time zones below.

Agenda

April 28, 2022

Main Schedule

7:50 AM - 8:00 AM
Welcome & Introduction
Patti Power (Divisional Head Gynecologic Oncology at H Bliss Cancer Center)
8:00 AM - 8:40 AM
A Multidisciplinary Approach to the Management of Obesity in the Gynecologic Oncology Patient
At the end of this session, participants will learn to:
1. Review the intersection between obesity and gyne oncology​
2. Weight bias in medicine (and how we need to do better)​
3. Explore compassionate ways to address obesity with your patients​
4. Understand effective multidisciplinary treatment for obesity​
Sasha High, FRCPC, ABOM (Founder and CEO of High Metabolic Clinic)
8:40 AM - 9:20 AM
Sarcopenic Obesity: A New Face of an Old Problem in Gynecological Cancer and How Nutrition Can Help
At the end of this session, participants will be: 1. Describe hidden abnormalities in body composition. 2. Recognize the prevalence and significance of sarcopenic obesity in gynecological cancer. 3. Explain how targeted nutrition intervention can prevent/treat sarcopenic obesity.
Carla Prado (Professor, Department of Agricultural, Food and Nutritional Science at University of Alberta)
9:20 AM - 10:00 AM
Incorporating Frailty Into the Treatment Plan of the Gynecologic Oncology Patient
At the end of this session, participants will be able to:​
1. Define frailty​
2. Describe the scope of the problem​
3. Explain how to recognize frailty in clinical practice​
4. Understand how frailty should impact treatment planning in the Gyn Onc patient
Erin Dean (MD at CancerCare Manitoba)
10:00 AM - 10:30 AM
First Break
10:30 AM - 11:10 AM
PARP Inhibitors in Ovarian Cancer – Beyond the Basis
At the end of this session, participants will:​ 1. Recognize indication of PARP inhibitor in practice 2. understand Biomarkers of response and resistance​ 3. Discuss what’s next: potential new indication, new PARPi, new target​
Stephanie Lheureux, MD, PhD (Clinician Investigator at Princess Margaret Cancer Centre)
11:10 AM - 11:50 AM
ICYMI ‘in case you missed it’ Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial- Gershenson et al.
At the end of this session, participants will​:
Understand the role of the MAPK pathway in low grade serous ovarian cancer​, Describe the role of MEK inhibition in the treatment of women with LGSC​ and Explain the benefits of trametinib compared to standard treatment in ou
Tamara Kuzma (Gynecologic Oncology Fellow at Tom Baker Cancer Centre, University of Calgary)
11:50 AM - 12:30 PM
ICYMI ‘In Case You Missed It’ Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2-Swisher et al.
At the end of this session, participants will be:​ Familiar with the use of PARP in treatment of relapsed HGOC​, Familiar with genetic and epigenetic molecular profiling predicting response in HGOC ​ and Describe cross-resistance mechanisms to platinum and PAPRi​
Vishaal Gupta, MD, FRCSC (Gynaecologic Oncology Clinical Fellow at McGill University)
12:30 PM - 1:00 PM
Second Break
1:00 PM - 1:40 PM
Management of Recurrent Uterine Leiomyosarcoma
At the end of this session, participants will be:​ Updated on the current standard of care for managing recurrent uterine leiomyosarcoma​. Informed on active areas of research in advanced uterine leiomyosarcoma
Jonathan Noujaim (Hematologist and Medical Oncologist Consultant at Hôpital Maisonneuve-Rosemont)
1:40 PM - 2:20 PM
Role of Immune Therapy in Management of Endometrial Cancer
At the end of this presentation, participants will be:​ Familiar with the efficacy of checkpoint inhibitors and checkpoint inhibitors in combination with VEGF-TKIs in Endometrial Cancer. Understand common adverse events of these therapeutics​. Become more familiar with adverse event management
Vicky Makker (Medical Oncologist at Memorial Sloan Kettering Cancer Center)
2:20 PM - 3:00 PM
A Primer for Managing Immune-Related Toxicities in the Gynecologic Oncology Patient
At the end of this session, participants will be:
Familiar with the unique toxicity profile of immune checkpoint inhibitors, Discuss the treatment of patients with immune-related events and Recognize and treat immune-related toxicity at its early stages.
Teresa Petrella (Medical Oncologist at Sunnybrook Health Sciences Centre)
3:00 PM - 3:45 PM
Case Presentation & Panel Discussion
At the end of this presentation, participants will be:​
1. Familiar with the efficacy of checkpoint inhibitors and checkpoint inhibitors in combination with VEGF-TKIs in Endometrial Cancer​
2. Understand common adverse events of these therapeutics​
3. Become more familiar with adverse event management ​
Marie-Helene Auclair (Gyne oncologist at Hôpital Maisonneuve-Rosemont)
Vicky Makker (Medical Oncologist at Memorial Sloan Kettering Cancer Center)
Teresa Petrella (Medical Oncologist at Sunnybrook Health Sciences Centre)
3:45 PM - 3:50 PM
Closing Remarks
Patti Power (Divisional Head Gynecologic Oncology at H Bliss Cancer Center)

Speakers and Moderators

Marie-Helene Auclair (Gyne oncologist at Hôpital Maisonneuve-Rosemont)

Marie-Helene Auclair

Gyne oncologist at Hôpital Maisonneuve-Rosemont

Melica Brodeur (Research fellow at Memorial Sloan Kettering Cancer Center)

Melica Brodeur

Research fellow at Memorial Sloan Kettering Cancer Center

Erin Dean (MD at CancerCare Manitoba)

Erin Dean

MD at CancerCare Manitoba

Rachelle Findley (Gynecologic Oncologist at Nova Scotia Cancer Centre)

Rachelle Findley

Gynecologic Oncologist at Nova Scotia Cancer Centre

Vishaal Gupta, MD, FRCSC (Gynaecologic Oncology Clinical Fellow at McGill University)

Vishaal Gupta, MD, FRCSC

Gynaecologic Oncology Clinical Fellow at McGill University

Sasha High, FRCPC, ABOM (Founder and CEO of High Metabolic Clinic)

Sasha High, FRCPC, ABOM

Founder and CEO of High Metabolic Clinic

Tamara Kuzma (Gynecologic Oncology Fellow at Tom Baker Cancer Centre, University of Calgary)

Tamara Kuzma

Gynecologic Oncology Fellow at Tom Baker Cancer Centre, University of Calgary

Stephanie Lheureux, MD, PhD (Clinician Investigator at Princess Margaret Cancer Centre)

Stephanie Lheureux, MD, PhD

Clinician Investigator at Princess Margaret Cancer Centre

Vicky Makker (Medical Oncologist at Memorial Sloan Kettering Cancer Center)

Vicky Makker

Medical Oncologist at Memorial Sloan Kettering Cancer Center

Jonathan Noujaim (Hematologist and Medical Oncologist Consultant at Hôpital Maisonneuve-Rosemont)

Jonathan Noujaim

Hematologist and Medical Oncologist Consultant at Hôpital Maisonneuve-Rosemont

Teresa Petrella (Medical Oncologist at Sunnybrook Health Sciences Centre)

Teresa Petrella

Medical Oncologist at Sunnybrook Health Sciences Centre

Patti Power (Divisional Head Gynecologic Oncology at H Bliss Cancer Center)

Patti Power

Divisional Head Gynecologic Oncology at H Bliss Cancer Center

Carla Prado (Professor, Department of Agricultural, Food and Nutritional Science at University of Alberta)

Carla Prado

Professor, Department of Agricultural, Food and Nutritional Science at University of Alberta

Omar Touhami (CIUSSS du saguenay Lac-Saint-Jean)

Omar Touhami

CIUSSS du saguenay Lac-Saint-Jean

Sponsors and Partners

Planning Committee

The following provides you with the list of all the members of the CPD Program Planning Committee with their conflict of interest. 

PATTI POWER

CHAIR


Dr. Power is the Divisional Chief of Gynecologic Oncology within Eastern Health and is a MUN Associate Professor within the Women's Health program. She is a graduate of Memorial's Medical School and completed her fellowship in Gynecologic Oncology in Calgary as well as a Diploma in Clinical Epidemiology at Memorial. She has been an active mentor in the Obstetrics and Gynecology program at MUN for many years, is an active member of the Residency Training Program for Obstetrics and Gynecology and is the Competency by Design Lead for that program. She has been a Royal College examiner for Obstetrics and Gynecology for the past 5 years and has now joined the Gynecologic Oncology Royal College Nucleus Committee. She is past president of The Society of Canadian Colposcopists and previous chair of the Subspecialties Committee of Academic Professionals in Obstetrics and Gynecology (APOG) of Canada. She is also an active member of the Scientific Advisory Committee for the H. Bliss Murphy Cancer Center. She has a special interest in student well-being and looks forward to positively contributing to the success of Memorial's undergraduate and postgraduate medical students. 


Conflict of Interest Form (coming soon!)

HELEN MACKAY

EXECUTIVE REPRESENTATIVE / PRESIDENT


Dr. Helen MacKay is a Medical Oncologist and Professor of Medicine at the University of Toronto. She is Head of the Division of Medical Oncology and Hematology at the Odette Cancer Centre at Sunnybrook Health Sciences Centre, and Senior Scientist at the Sunnybrook Research Institute. Dr. MacKay's clinical practice and research focus is on gynecological cancers. Her research involves collaborating with translational and basic scientists in the development and validation of novel therapeutic strategies. She is the current President of the Society of Gynecologic Oncologists of Canada (GOC). She co-chairs the NCI (US), Ovarian Cancer Task Force. She also chairs the Ovarian Group and sits on the executive of the Gyne committee of the Canadian Cancer Trials Group (CCTG), and represents CCTG at the Gynecologic Cancer Intergroup. She is a past chair of both the Gynecologic Cancer Education and Scientific Committees for ASCO. With specific reference to uterine cancers, she is a member of the TRANSPORTEC group, and sits on the Corpus Committee of NRG, and was the co-chair of the NCI Endometrial Cancer Clinical Trials Planning Committee. 


Conflict of Interest Form (coming soon!)

ALON ALTMAN

EXECUTIVE REPRESENTATIVE / PRESIDENT-ELECT


Dr. Alon Altman is a professor of obstetrics, gynecology and reproductive sciences at the Rady Faculty of Health Sceinces. He is also a gynecologic oncologist at the Health Sciences Centre/Cancercare Manitoba.

He has a strong interest in undergraduate/postgraduate education and research.

Dr. Altman is the president elect for the Society of Gynecologic Oncology of Canada (GOC), the program director for the department of Obstetrics and Gynecology, chair of the University Medical Group (UMG), vice chair for the Medical Management Safety Committee (MMSC) at CancerCare Manitoba, the current Gynecologic oncology track lead for the FIGO 2021 Scientific planning committee and the previous co-chair of the Canadian Obstetrics and Gynecology Review program (COGRP).

He is actively involved in multiple university, national and international committees.


Conflict of Interest Form (coming soon!)

JACOB MCGEE

EXECUTIVE REPRESENTATIVE / SECRETARY-TREASURER


Jacob McGee is a gynecologic oncologist and an associate professor in the Schulich School of Medicine at Western University. He is the regional gynecologic oncology champion for southwestern Ontario, a Director for the Gynecologic Oncology Group of Ontario (GOGO), and the incoming Secretary-Treasurer for The Society of Gynecologic Oncology of Canada. His research interests include optimizing testing for hereditary cancer syndromes and outcomes research using ICES (institute for clinical evaluative sciences) datasets.   


Conflict of Interest Form (coming soon!)

STEPHEN WELCH

MEMBER



Conflict of Interest Form (coming soon!)

MARIE-HELENE AUCLAIR

MEMBER




Conflict of Interest Form (coming soon!)

OMAR TOUHAMI

MEMBER




Conflict of Interest Form (coming soon!)

JOANNE POWER

MEMBER / NURSE REPRESENTATIVE




Conflict of Interest Form (coming soon!)

RACHELLE FINDLEY

MEMBER / COMMUNICATIONS REPRESENTATIVE


Rachelle Findley hails from rural Southern Alberta. She completed her Bachelor of Science in Pharmacy at the University of Alberta and worked as a community pharmacist throughout her Medical degree in Edmonton. Obstetrics and Gynecology residency took her across the country to Halifax at Dalhousie University.

 

Having recently completed Gynecologic Oncology fellowship through the University of Calgary in 2021, she has since worked with the Gynecologic Oncology team at the Allan Blair Cancer Centre in Regina and started a master's program with the Johnson Shoyama Graduate School of Public Policy.



Conflict of Interest Form (coming soon!)

MARK CAREY

MEMBER / CHAIR, BIOLOGY COURSE


He completed his medical degree and Obstetrics & Gynaecology residency at the University of Western Ontario, a fellowship in Gynaecologic Oncology at the University of Toronto and McMaster University, and a research fellowship in the Department of Systems Biology at the University of Texas, MD Anderson Cancer Centre. He runs his research program through OvCaRe and has funding through private donations and his medical corporation to support his laboratory staff. He is Co-Investigator on a recent grant award from the Cancer Research Society with Dr. Cheng-Han Lee, and has done contract research for investigational drug testing. His laboratory has been supported as well by research funds from Dr. Dianne Miller and the Division of Gyn Oncology, the BC Cancer Agency, the Carraresi Foundation OvCaRe Research Grant, and VGH and UBC Hospital Foundations. Mark regularly supervises PhD and MSc candidates and is a member of the department's Research Advisory Committee.



Conflict of Interest Form (coming soon!)

TOMER FEIGENBERG

MEMBER / CHAIR, AGM PLANNING COMMITTEE




Conflict of Interest Form (coming soon!)

MELICA BRODEUR

MEMBER



Conflict of Interest Form (coming soon!)

SARAH SINASAC

EXECUTIVE REPRESENTATIVE / DIRECTOR OF EDUCATION


Dr. Sinasac is a Gynecologic Oncologist at The Ottawa Hospital, and an Assistant Professor at the University of Ottawa. She completed residency in Obstetrics and Gynecology and fellowship in Gynecologic Oncology at the University of Toronto. During fellowship she completed her Master's degree in Public Health at Harvard University. She is the Gynecologic Oncology Fellowship Program Director at the University of Ottawa. She is the Chair of the Education Committee at the GOC, and the founder and co-Chair of the Community of Practice in Obesity. She has extensive training and experience in advanced laparoscopic surgery and has an interest in surgical skills education. 


Conflict of Interest Form (coming soon!)

LAURENCE BERNARD

MEMBER




Conflict of Interest Form (coming soon!)

SABRINA PIEDIMONTE

MEMBER / FELLOW REPRESENTATIVE




Conflict of Interest Form (coming soon!)

Recordings

Session I

A Multidisciplinary Approach to the Management of Obesity in the Gynecologic Oncology Patient - Dr. Sasha High


At the end of this session, participants will learn to:

  1. Review the intersection between obesity and gyne oncology​.
  2. Weight bias in medicine (and how we need to do better)​.
  3. Explore compassionate ways to address obesity with your patients​.
  4. Understand effective multidisciplinary treatment for obesity​.


Access the recording.

Sarcopenic Obesity: A New Face of an Old Problem in Gynecological Cancer and How Nutrition Can Help - Dr. Carla Prado


At the end of this session, participants will be:

  1. Describe hidden abnormalities in body composition.
  2. Recognize the prevalence and significance of sarcopenic obesity in gynecological cancer.
  3. Explain how targeted nutrition intervention can prevent/treat sarcopenic obesity.


Access the recording.

Incorporating Frailty Into the Treatment Plan of the Gynecologic Oncology Patient - Dr. Erin Dean


At the end of this session, participants will be able to:​

  1. Define frailty​.
  2. Describe the scope of the problem​
  3. Explain how to recognize frailty in clinical practice.
  4. Understand how frailty should impact treatment planning in the Gyn Onc patient.


Access the recording.

Session II

PARP Inhibitors in Ovarian Cancer – Beyond the Basis - Dr. Stephanie Lheureux


At the end of this session, participants will:​

  1. Recognize indication of PARP inhibitor in practice.
  2. Understand Biomarkers of response and resistance.
  3. Discuss what's next: potential new indication, new PARPi, new target​.


Access the recording.

ICYMI 'in case you missed it' Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial- Gershenson et al. - Dr. Tamara Kuzma


At the end of this session, participants will​:

  1. Understand the role of the MAPK pathway in low grade serous ovarian cancer​.
  2. Describe the role of MEK inhibition in the treatment of women with LGSC​.
  3. Explain the benefits of trametinib compared to standard treatment.


Access the recording.

ICYMI 'In Case You Missed It' Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2-Swisher et al. - Dr. Vishaal Gupta


At the end of this session, participants will be:​

  1. Familiar with the use of PARP in treatment of relapsed HGOC​.
  2. Familiar with genetic and epigenetic molecular profiling predicting response in HGOC.
  3. Describe cross-resistance mechanisms to platinum and PARPi​.


Access the recording.

Session III

Management of Recurrent Uterine Leiomyosarcoma - Dr. Jonathan Noujaim


At the end of this session, participants will be:​

  1. Updated on the current standard of care for managing recurrent uterine leiomyosarcoma​.
  2. Informed on active areas of research in advanced uterine leiomyosarcoma.


Access the recording.

Role of Immune Therapy in Management of Endometrial Cancer - Dr. Vicky Makker


At the end of this presentation, participants will be:​

  1. Familiar with the efficacy of checkpoint inhibitors and checkpoint inhibitors in combination with VEGF-TKIs in Endometrial Cancer.
  2. Understand common adverse events of these therapeutics​. Become more familiar with adverse event management.


Access the recording.

A Primer for Managing Immune-Related Toxicities in the Gynecologic Oncology Patient - Dr. Teresa Petrella


At the end of this session, participants will be:

  1. Familiar with the unique toxicity profile of immune checkpoint inhibitors.
  2. Discuss the treatment of patients with immune-related events.
  3. Recognize and treat immune-related toxicity at its early stages.


Access the recording.

Case Presentation & Panel Discussion - Drs. Marie-Helene Auclair, Vicky Makker and Teresa Petrella


At the end of this presentation, participants will be:

  1. Familiar with the efficacy of checkpoint inhibitors and checkpoint inhibitors in combination with VEGF-TKIs in Endometrial Cancer​.
  2. Understand common adverse events of these therapeutics​.
  3. Become more familiar with adverse event management.


Access the recording.